



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Reply, please refer to:

Jacques DUMAS et al.

Confirmation No.: 8328

Serial No.: 09/458,014

Examiner: MITCHELL, Gregory W.

Filed: December 10, 1999

Group Art Unit: 1617


Title: INHIBITION OF P38 KINASE USING ACTIVITY SUBSTITUTED
HETEROCYCLIC UREAS

REPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In response to the thirty-day notice dated August 17, 2006, applicants revise the election made in response to the restriction requirement to Group II, directed to 1,2 oxazoles so as to encompass the new elected species, compound 120, having the following formula:



Applicants maintain that no evidence has been presented showing it would not be an undue burden to examine the full scope of the compounds of formula I. In fact, before the RCE's were filed in this application, the full scope of the original method claims had been examined. No evidence or reason has been presented why the continued examination requires a restriction of the subject matter claimed.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,


Richard J. Traverso, Reg. No. 30,595
Attorneys for Applicants

MILLEN, WHITE, ZELANO &
BRANIGAN, P.C.
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201

Date: September 13, 2006